# Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients

> **NCT05611463** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 25 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab Plus Docetaxel and Cisplatin

## Key facts

- **NCT ID:** NCT05611463
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-02
- **Primary completion:** 2022-12-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611463, "Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05611463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*